Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
73 hedge funds and large institutions have $175M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 11 closing their positions.
306% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $562K
0% more funds holding
Funds holding: 73 → 73 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
2% less capital invested
Capital invested by funds: $179M → $175M (-$3.75M)
4% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Alydar Partners
Boston,
Massachusetts
|
+$2.17M |
| 2 |
Axa
Paris,
France
|
+$1.73M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$1.65M |
| 4 |
D.E. Shaw & Co
New York
|
+$1.31M |
| 5 |
CI
Cowen Inc
New York
|
+$1.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.06M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.03M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$798K |
| 4 |
IGIM
I.G. Investment Management
Winnipeg,
Manitoba, Canada
|
-$615K |
| 5 |
MOACM
Mutual of America Capital Management
New York
|
-$577K |
VIRX Hedge Fund Activity: Q4 2013 in Review
73 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2013, worth a combined $175M — down 2.1% from $179M a quarter earlier.
Fund positioning in VIRX was balanced in Q4 2013: 11 funds opened new positions, 11 closed out, 23 added to existing stakes and 24 trimmed.
The largest buyer was Alydar Partners, adding an estimated $2.17M. The largest seller was Fidelity Investments, cutting an estimated $4.06M.
- 73 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $175M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2013, down 2.1% quarter-over-quarter.
- 11 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2013 and 11 closed out, a net change of 0 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2013 was Alydar Partners, an estimated $2.17M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2013 was Fidelity Investments, an estimated $4.06M sold.
Based on aggregated 13F filings for Q4 2013.